Press release
June 26, 2026
Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma
Replimune Group, Inc. (REPL)
FDA decision expected by August 2, 2026 WOBURN, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, announced today that the U.S.